



## Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 20, 2018

BOULDER, Colo., Dec. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

**Event:** 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference  
**Presenter:** Ron Squarer, Chief Executive Officer, Array BioPharma  
**Date:** Monday, January 7, 2019  
**Time:** 11:30 a.m. Pacific Time  
**Presentation Webcast:** <https://jpmorgan.metameetings.net/events/healthcare19/sessions/24031-array-biopharma-inc/webcast>  
**Breakout Webcast:** <https://jpmorgan.metameetings.net/events/healthcare19/sessions/24357-array-biopharma-inc-q-a/webcast>

### About Array BioPharma

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI<sup>®</sup> (encorafenib) capsules in combination with MEKTOVI<sup>®</sup> (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a *BRAF*<sup>V600E</sup> or *BRAF*<sup>V600K</sup> mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in *BRAF*-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi<sup>®</sup> (larotrectinib, partnered with Loxo Oncology) is approved in the United States and Ganovo<sup>®</sup> (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit [www.arraybiopharma.com](http://www.arraybiopharma.com) or follow @arraybiopharma on Twitter and LinkedIn.

### CONTACT:

Andrea N. Flynn, Ph.D.  
Senior Director, Investor Relations & Corporate Communications  
(303) 381-6600  
[ir@arraybiopharma.com](mailto:ir@arraybiopharma.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-300769032.html>

SOURCE Array BioPharma Inc.